Navigation Links
Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference
Date:5/21/2008

17/86 subjects), with no

differences among the active drug group and the placebo group

* Plasma levels of larazotide acetate were below the limits of

quantification (0.5 ng/ml) in all groups at days 0, 7 and 14

"Although the primary study outcome was not statistically significant, a great deal was learned about the potential effects of larazotide acetate and the secondary outcome data is very positive. Further, important new information was gained about the best way to run a celiac disease clinical trial. This trial marks the beginning of a new era in celiac therapeutics where modalities beyond diet alone have the ability to improve the lives of our patients," stated Daniel Leffler, MD a gastroenterologist from Beth Israel Deaconess Medical Center.

"We are very encouraged by the clear trend in the reduction of intestinal permeability and the signs and symptoms of gluten exposure in patients with celiac disease. We have applied the knowledge gained in this Phase IIa clinical trial to a larger Phase IIb gluten challenge study which is currently ongoing. In addition, we have recently initiated a clinical trial in 106 active celiac disease patients. Alba is committed to developing and studying new treatment options for patients with celiac disease," stated Dr. Francisco Leon, Head of Clinical Research and Development at Alba. For more information about Alba's clinical trials, please visit the http://www.clinicaltrials.gov web site and search for Alba Therapeutics.

About Celiac Disease

Celiac disease is a lifelong T-cell mediated auto-immune disorder, which occurs in individuals who are genetically susceptible and is characterized by small intestinal inflammation, injury and intolerance to gluten. CD is a growing public health concern, affecting approximately 3 million people in the United States and over 6.5 million people worldwide. People with CD cannot tole
'/>"/>

SOURCE Alba Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. PTC Therapeutics Announces Data Supporting Cough Frequency as a New Outcome Measure in Evaluating Treatments for Cystic Fibrosis
2. Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease
3. PacificGMP Completes GMP Product Fill for Trius Therapeutics
4. Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy
5. Vicus Therapeutics Records Last Patient Visit of Phase 2, VT-122 Trial for the Treatment of Cachexia in Patients With Advanced Lung Cancer
6. Cara Therapeutics Initiates Phase 1 Clinical Trial of Novel Analgesic, CR845
7. PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy
8. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
9. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
10. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
11. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Germany , July 30, 2014  invendo ... and computer-assisted ("robotic") colonoscopy system, today announced the appointment ... medical device executive, as a new member of its ... highly respected global visionary in the medical device industry. ... and Chief Executive Officer at Given Imaging Ltd. (NASDAQ/TASE: ...
(Date:7/30/2014)... TARRYTOWN, N.Y. and PARIS ... REGN ) and Sanofi (EURONEXT: SAN and ... new Phase 3 ODYSSEY trials of alirocumab in people ... greater percent reduction from baseline in low-density lipoprotein cholesterol ... comparator.  Alirocumab is an investigational monoclonal antibody targeting PCSK9 ...
(Date:7/30/2014)... VEGAS , July 30, 2014  DigiPath, Inc. ... that is expanding into the cannabis testing and education ... in its business and affairs not previously disclosed or, ... the recent unusual market action. "We have ... over the last three trading days," said Steve ...
Breaking Medicine Technology:invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 2invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8DigiPath No New Corporate Developments 2
(Date:7/31/2014)... Pass, OR (PRWEB) July 31, 2014 Sales ... 12-percent from 2013 to 2014, according to radio talk show ... has been experiencing rapid growth since 1990. The US economy ... Sharon Kleyne Hour Power of Water radio show, reported this ... Bragg Live Foods, a worldwide manufacturer of organic and natural ...
(Date:7/31/2014)... According to new research report ... by Type (Tofu, Tofu-Based Product, Tempeh, TVP, Seitan, ... Trends & Forecasts to 2019", defines and segments ... and forecasting of the market value of sources, ... also identifies the driving and restraining factors for ...
(Date:7/31/2014)... July 31, 2014 Care Communications, Inc., ... outsourcing firm, has received the Elite Award for “Recruitment, ... Resources, one of twelve elite awards presented as part ... to Work For” 2014 awards competition. This marks ... Elite Award in the competition. CARE has also been ...
(Date:7/31/2014)... July 31, 2014 Daily Gossip reveals in ... help sufferers discover some breakthrough weight loss tips. , ... tips and recommendations are very simple to implement. Users don’t ... foods, with no need to start counting calories. , ... who in fact created a 12 weeks weight loss program ...
(Date:7/31/2014)... 31, 2014 In its latest blog post, ... believes that having family close by during a stay in ... the process is successful, is looking at 10 tips to ... , “Addiction recovery is a lifelong process, and one that ... committed to without compromise,” commented Best Drug Rehabilitation’s CEO ...
Breaking Medicine News(10 mins):Health News:Organic Food Industry Grew 12% in 2013-2014 Reports Sharon Kleyne Hour Power of Water Host 2Health News:Organic Food Industry Grew 12% in 2013-2014 Reports Sharon Kleyne Hour Power of Water Host 3Health News:Meat Substitutes Market Worth $4,622.4 Million by 2019 - New Report by MarketsandMarkets 2Health News:Meat Substitutes Market Worth $4,622.4 Million by 2019 - New Report by MarketsandMarkets 3Health News:Care Communications, Inc. Named an Elite Award Winner Among Top Chicago Employers 2Health News:New Best Drug Rehabilitation Blog Posts Looks at 10 Tips for Coping After Drug or Alcohol Rehab 2
... century, John Snow mapped cases of cholera in Soho, London, ... water pump. Now, in a twenty-first century equivalent, scientists funded ... the latest in gene sequencing technology and global positioning system ... trace its source. Typhoid fever is caused by two ...
... Updated guidelines from the American Academy of Pediatrics (AAP) ... (ADHD) in younger children and in adolescents. Emerging ... in children from ages 4 to 18 (the previous ... 6 to 12). The new guidelines describe the special ...
... , SATURDAY, Oct. 15 (HealthDay News) -- Head injuries are ... a new study finds. Researchers examined data on 52 ... at a pediatric trauma center between 2003 and 2011. The ... 10 and the most common cause of injury was hitting ...
... BOSTON - An in-hospital delay of appendicitis treatment ... likelihood of complications, including perforation and abscess formation; ... according an abstract presented Saturday, Oct. 15 at ... and Exhibition in Boston. In "Missed Opportunities ...
... 14 (HealthDay News) -- Flu activity levels in the United ... get a flu shot, the U.S. Centers for Disease Control ... for the 2011-2012 flu season, the federal agency also said ... the U.S. supply is projected to be at an all-time ...
... One in six people in the United States is affected ... multiple sclerosis, and more research is required to find new ... mark its 20th anniversary, the foundation has released a video ... ongoing research. "Brain disease is in the news every ...
Cached Medicine News:Health News:Google Earth typhoid maps reveal secrets of disease outbreaks 2Health News:Google Earth typhoid maps reveal secrets of disease outbreaks 3Health News:AAP expands ages for diagnosis and treatment of ADHD in children 2Health News:Delayed pediatric appendicitis treatment linked to complications, and even death 2Health News:Get Your Flu Shot Now, CDC Urges 2Health News:Foundation Aims to Raise Awareness of Brain Diseases 2
... patient tracking and billing. ... complete Handheld application, a ... complete CPT™ and ICD-9-CM ... AMA. Designed for any ...
... ToolBox is an advanced medical ... Emergency, Pediatric Dosing and Critical ... is a logical complement to ... as the Daviss Drug Guide, ...
... the handheld version of ... drug interaction analyzer covering ... generic drugs. iFacts™ enables ... to accurate and reliable ...
A handy, quick reference for physicians, nurses, and other health care providers treating cancer patients....
Medicine Products: